Table 1 A table showing the methodological score, numbers, duration of treatment, outcomes measures and standardised mean difference for pain and function
Author | Quality Score[10] (0–5) | Number receiving PEMF | Number receiving placebo | Duration of Treatment (weeks) | Pain Outcome | Functional Outcome | Standardised Mean Difference for pain (95%CI) | Standardised Mean Difference for function (95%CI) |
|---|---|---|---|---|---|---|---|---|
Klaber-Moffett et al 1996[16] | 5 | 26 | 22 | 3 | VAS Pain Scale | None reported | -0.03 (-0.59 to 0.54) | None reported |
Pipetone et al 2001[14] | 5 | 34 | 35 | 6 | WOMAC Pain Scale | WOMAC Physical Function Scale | -0.10 (-0.58 to 0.37) | -0.33 (-0.80 to 0.15) |
Thamsborg et al 2005[15] | 3 | 42 | 41 | 6 | WOMAC Pain scale | WOMAC Physical Function Scale | -0.31 (-0.74 to 0.12) | -0.58 (-1.02 to -0.14) |
Laufer et al 2005[17] | 3 | 27 | 31 | 3 | WOMAC Pain scale | WOMAC Physical Function Scale | -0.05 (-0.57 to 0.46) | -0.09 (-0.60 to 0.43) |
Callaghan et al 2005[18] | 4 | 9 | 9 | 2 | VAS Pain Scale | AIMS | -0.33 (-1.26 to 0.61) | 0.00 (-0.92 to 0.92) |
TOTAL | Â | 138 | 138 | Â | Â | Â | -0.16 (-0.39 to 0.08) | -0.33 (-0.59 to -0.07) |